Technical Analysis for CKPT - Checkpoint Therapeutics, Inc.

Grade Last Price % Change Price Change
D 1.89 -1.56% -0.03
CKPT closed down 1.56 percent on Monday, March 18, 2024, on 66 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 28
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish -1.56%
NR7 Range Contraction -1.56%
Narrow Range Bar Range Contraction -1.56%
Inside Day Range Contraction -1.56%
Gapped Up Strength -1.56%
Oversold Stochastic Weakness -1.56%
50 DMA Resistance Bearish 2.16%

   Recent Intraday Alerts

Alert Time
50 DMA Resistance about 8 hours ago
60 Minute Opening Range Breakout about 8 hours ago
Up 3% about 8 hours ago
Up 2% about 9 hours ago
Outside Day about 12 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Checkpoint Therapeutics, Inc. Description

Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Antibodies Cancer Immunotherapy Chemotherapy Epidermal Growth Factor Receptor Immune Checkpoint Solid Tumor Cancers Checkpoint Inhibitor Necrosis Tumor Necrosis Factor Immuno Oncology Biopharmaceutical Tumor Necrosis

Is CKPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.2899
52 Week Low 1.3
Average Volume 596,527
200-Day Moving Average 2.21
50-Day Moving Average 1.98
20-Day Moving Average 2.06
10-Day Moving Average 2.05
Average True Range 0.14
RSI (14) 42.20
ADX 17.88
+DI 19.50
-DI 19.35
Chandelier Exit (Long, 3 ATRs) 1.94
Chandelier Exit (Short, 3 ATRs) 2.27
Upper Bollinger Bands 2.32
Lower Bollinger Band 1.79
Percent B (%b) 0.19
BandWidth 26.02
MACD Line -0.02
MACD Signal Line 0.01
MACD Histogram -0.0337
Fundamentals Value
Market Cap 45.55 Million
Num Shares 24.1 Million
EPS -4.38
Price-to-Earnings (P/E) Ratio -0.43
Price-to-Sales 287.18
Price-to-Book 8.56
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.10
Resistance 3 (R3) 2.11 2.06 2.06
Resistance 2 (R2) 2.06 2.01 2.05 2.05
Resistance 1 (R1) 1.98 1.98 1.95 1.96 2.04
Pivot Point 1.92 1.92 1.91 1.91 1.92
Support 1 (S1) 1.84 1.87 1.81 1.82 1.74
Support 2 (S2) 1.78 1.84 1.78 1.73
Support 3 (S3) 1.70 1.78 1.72
Support 4 (S4) 1.68